CRBU Caribou Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRBU

Price (delayed)

$1.29

Market cap

$138.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.08

Enterprise value

$138.76M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 37

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior ...

Highlights
The revenue has increased by 50% year-on-year
CRBU's gross profit is up by 50% YoY
The equity fell by 41% YoY and by 3.8% QoQ
Caribou Biosciences's debt has increased by 3.1% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://cariboubio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CRBU

CRBU stock price

How has the Caribou Biosciences stock price performed over time
Intraday
-3.73%
1 week
3.2%
1 month
-22.29%
1 year
-30.65%
YTD
-18.87%
QTD
-26.7%

Financial performance

How have Caribou Biosciences's revenue and profit performed over time
Revenue
$6.14M
Gross profit
$6.14M
Operating income
-$113.37M
Net income
-$103.4M
Gross margin
100%
Net margin
-1,684.4%
Caribou Biosciences's net margin has soared by 58% YoY and by 22% from the previous quarter
The company's operating margin has surged by 56% YoY and by 17% QoQ
The revenue has increased by 50% year-on-year
CRBU's gross profit is up by 50% YoY

Price vs fundamentals

How does CRBU's price correlate with its fundamentals

Growth

What is Caribou Biosciences's growth rate over time

Valuation

What is Caribou Biosciences stock price valuation
P/E
N/A
P/B
1.3
P/S
21.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.6
Caribou Biosciences's EPS has increased by 39% YoY and by 24% QoQ
The equity fell by 41% YoY and by 3.8% QoQ
The P/B is 16% less than the last 4 quarters average of 1.6 but 3.8% more than the 5-year quarterly average of 1.3
The revenue has increased by 50% year-on-year
CRBU's P/S is 28% below its 5-year quarterly average of 30.8 and 28% below its last 4 quarters average of 30.7

Efficiency

How efficient is Caribou Biosciences business performance
Caribou Biosciences's return on sales has surged by 58% YoY and by 22% QoQ
The ROE has contracted by 24% YoY but it has grown by 11% from the previous quarter
CRBU's return on invested capital is up by 14% since the previous quarter but it is down by 6% year-on-year
CRBU's ROA is up by 13% since the previous quarter but it is down by 10% year-on-year

Dividends

What is CRBU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRBU.

Financial health

How did Caribou Biosciences financials performed over time
The company's total assets fell by 35% YoY and by 4.2% QoQ
The company's total liabilities fell by 18% YoY and by 4.9% QoQ
Caribou Biosciences's debt is 73% less than its equity
Caribou Biosciences's debt to equity has soared by 69% YoY and by 3.8% from the previous quarter
The equity fell by 41% YoY and by 3.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.